Updated:
Ysios Capital Partners
Ysios Capital is a major European venture capital firm and leading life sciences investor financing highly innovative biotech companies worldwide.
Ysios Capital Partners
Ysios Capital is a major European venture capital firm and leading life sciences investor financing highly innovative biotech companies worldwide. The firm provides biotech ventures with resources to develop novel therapies for indications with high unmet medical needs, focusing exclusively on innovative therapeutic drugs. It fosters positive impact on patients and society by funding transformative treatments.
General information
Firm type
Private Equity
Year founded
2008
AUM
>€400M (per the firm, 2026)
Location
Region
Europe
Country
Spain
City
Donostia-San Sebastian
Corporate office
Donostia-San Sebastian, Spain
Additional offices
Barcelona, Spain
Principals
Joël Jean-Mairet
Partner
Julia Salaverría
Partner
Karen Wagner
Partner
Joan Perelló
Partner
Cristina Garmendia
Partner
Jordi Xiol
Partner
Guillem Laporta
Partner
Thomas Harth
Partner
Arturo Urrios
Partner
Iñigo López-Huerta
Partner
Sector focus
Frequently asked questions
Does Ysios participate in fund commitments or only direct deals?
Ysios invests directly into private biotech companies and does not operate as a fund-of-funds allocator. Its disclosures show equity positions in portfolio companies at the board level, with a consistent pattern of direct lead or co-lead investments. The firm has not disclosed any LP commitments to other venture funds; its model is direct therapeutic company-building.
What investment stages does Ysios typically target?
Ysios invests from seed through pre-IPO, with a concentration on early-stage and expansion-stage private biotech companies (per Altss research record, 2026). The firm's strategy includes spin-off vehicles and company creation via the InceptionBio fund, covering the earliest phases of therapeutic development. It maintains positions through later rounds, as evidenced by retained stakes in portfolio companies that subsequently listed on NASDAQ, including Aura Biosciences and Mineralys Therapeutics.
Which therapeutic areas does Ysios explicitly focus on?
The firm focuses exclusively on novel therapeutics for indications with high unmet medical need, spanning oncology (Adcendo, LAVA Therapeutics), CNS disorders (Synendos, Minoryx), cardiovascular conditions (CorWave, Mineralys Therapeutics), ophthalmology (SparingVision), metabolic disease (NorthSea Therapeutics) and reproductive medicine (ReproNovo). This therapeutic breadth within a single asset-class constraint — only drug and biologic developers — means Ysios operates as a sector-specialist rather than a platform generalist.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: